Desirox中文版的说明书

Chinese version of the instruction manual

[Drug Name] Deferasirox, Enrig, Deferasirox, Desirox

[Desiro Indications] Desirox is used to treat chronic iron overload caused by frequent blood transfusions (monthly administration of concentrated red blood cells ≥7mL/kg) in patients with beta-thalassemia older than 6 years old; iron overload caused by children under 6 years old and other transfusion-dependent diseases.

[Desiro usage and dosage] The recommended starting daily dose is 20mg/kg. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (ie, more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered.

For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered.

In patients who have already responded well to deferoxamine therapy, an initial dose of Desirox equivalent to half the deferoxamine dose may be considered.

[Desiro Side Effects] Common side effects: diarrhea, vomiting, headache, abdominal pain, fever, rash, increased serum creatinine, etc.

Other less common side effects: increased liver enzymes, cough, throat irritation, hives.

[Notes on Desiro]

1. Desirox may cause a rash. Generally, the rash will disappear automatically without the need to adjust the dose or stop the medication. If the condition is severe or persistent, the medication should be stopped.

2. The patient’s vision or hearing may be affected.

3. It should be taken 30 minutes before meals.

4. It should be taken at the same time every day.

[Contraindications of Desirox] Desirox is contraindicated in persons with known allergies to the active ingredients or any excipients. Desirox should not be combined with other iron chelation treatments as the safety of such combined use has not been established.

It is contraindicated in patients with a creatinine clearance rate of 2 times the upper limit of the normal age range; patients with poor general condition, high-risk myelodysplastic syndrome (MDS) or advanced malignant tumors.